NeuroScientific Biopharmaceuticals NSB.AX · AUD

Its shares trade on ASX under the ticker NSB.AX. It has been listed since 27 July 2018. In the fiscal year to 30 June 2025, it reported revenue of A$166,100 and a net loss of A$1.8m. At that date it held total assets of A$17.0m and shareholders' equity of A$16.8m.

Neuroscientific Biopharmaceuticals Ltd. engages in researching and developing novel peptide-based pharmaceutical products. The Company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Christopher NtoumenopoulosNon-Executive Chairman of the Board
• Mr. Nathan SmithChief Executive Officer
• Mr. Dougal ThringChief Operating Officer
• Dr. Anton UvarovExecutive Director, since 2018A$285,878
• Mr. Simon ScottDirector of Clinical Development
• Mr. Chris AchurchCompany Secretary
• Mr. Robert MckenzieDirector
• Mr. Clarke BarlowNon-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.